ÂÜÀòÂÒÂ×

Marianna Zavodovskaya is a seasoned research scientist specializing in biomarker development and translational medicine, currently serving as a Biomarker Lead at Gilead Sciences since November 2022. With notable experience at Arch Oncology as the AD Translational Medicine Translational Lead, Zavodovskaya supported a Phase I/II study for Multiple Myeloma, led pharmacokinetics initiatives, and guided biomarker processes. Previous roles at IDEAYA Biosciences and Gilead Sciences showcased leadership in various clinical biomarker projects and contributed to strategic clinical decisions, earning multiple awards for outstanding performance. Earlier career accomplishments include senior positions at Celgene, Cytokinetics, and UCSF, where Zavodovskaya was involved in developing translational data and clinical biomarker assays. Educational credentials include a Master's in Physiology from Penn State University and a BA in Molecular and Cell Biology from the University of California, Berkeley, complemented by a recent certificate in drug discovery and development from UCSF-Stanford CERSI.